A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer
Rebecca Kristeleit(Guy's and St Thomas' NHS Foundation Trust), Udai Banerji(Institute of Cancer Research), Mark Kowalski(College of San Mateo), Louise Carter(The Christie NHS Foundation Trust), Ruth Plummer(National Health Service), Stefan N. Symeonides(NHS Lothian), Robert H. Jones(Velindre NHS Trust), Sarah P. Blagden(Churchill Hospital), Sarah Danson(Weston Park Cancer Centre), Barbara Klencke, Debashis Sarker(King's College - North Carolina), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), Gareth J. Veal(Newcastle University), T.R. Jeffry Evans(University of Glasgow)
Cited by 36
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction
|New England Journal of Medicine|2011|877
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
|British Journal of Cancer|2015|638